Start conversations about changing the price of Kovide the paths
In recent weeks there has been an increase in the number of newly discovered cases of CVID-19 patients, increasing the number of hospitalized patients both in clinical pathways and in intensive wards.
By associations and associations of hospitals received information on the costs of hospital medical care facilities in the treatment of patients with CVID-19 . Data show that in many cases the aggregated costs incurred by hospitals exceed the financing of this treatment by paying in the clinical paths defined in R & D and in some cases and in the CPP for intensive care.
Given the expected increase in the number of hospitalized patients with COVID-19, the fastest possible option to support the BMP medical institutions in this situation is to raise clinical path prices No. 39, No. 48 and No 104 in cases where Treatment of patients with proven Covid-19 . Therefore, the GLS proposes to draw up an additional agreement on the R & D for medical activities 2020-2022, with the increase in the clinical paths given since 01.08.2021 and applies to the time of the act of the Minister of Health Act anti-epidemic measures on the territory of the whole country.
Писмото до НЗОК може да намерите тук
